LRPA
CRSP icon

L. Roy Papp & Associates’s CRISPR Therapeutics CRSP Stock Holding History

L. Roy Papp & Associates’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,000
Closed -$459K – 173
2020
Q4 		$459K Hold
3,000
– – 0.05% 135
2020
Q3 		$251K Hold
3,000
– – 0.03% 155
2020
Q2 		$220K Buy
+3,000
New +$175K 0.03% 157

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

L. Roy Papp & Associates's CRSP Position: Q1 2021 in Review

L. Roy Papp & Associates sold out of CRISPR Therapeutics (CRSP) in Q1 2021, closing a stake of 3,000 shares — an estimated $459K sold.

L. Roy Papp & Associates first reported a position in CRSP in Q2 2020 and held it in 3 quarters. The position peaked at $459K in Q4 2020. 443 funds tracked by Wall St. Rank hold CRSP as of Q1 2021.

  • L. Roy Papp & Associates reported no remaining CRISPR Therapeutics position as of Q1 2021 after selling out during the quarter.
  • L. Roy Papp & Associates sold 3,000 CRISPR Therapeutics shares in Q1 2021, an estimated $459K.
  • L. Roy Papp & Associates first reported a position in CRISPR Therapeutics in Q2 2020 and held it in 3 quarters.
  • L. Roy Papp & Associates's CRISPR Therapeutics position peaked at $459K in Q4 2020.
  • 443 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2021.

Based on L. Roy Papp & Associates's 13F filing for Q1 2021, filed 6 May 2021.